Cagrilintide
Also called AM833
Subcutaneous (under the skin)Human study reference
Research reference
Human study
Cagrilintide phase 2 dose-finding trial
Separate once-weekly groups targeting 0.3, 0.6, 1.2, 2.4 or 4.5 mg
26 weeks, including up to 6 weeks of escalation; 6 weeks of off-drug follow-up
Lau et al., Lancet (2021) ↗When results may show
- When change was measured
- Weight change was compared at week 26. The separate dose groups are not steps in one person's plan.
- When to assess
- 26 weeks, including up to 6 weeks of escalation; 6 weeks of off-drug follow-up
- Conditions and limitations
- Adults with overweight or obesity. No universal starter, maintenance cycle or blend ratio follows from these groups.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Sources: Lau et al., Lancet (2021)
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Combination evidence and cautions
What is known and unknown about Cagrilintide alongside other compounds or medicines.
Key properties
- Formula
- C194H312N54O59S2
- Mol. weight
- 4,409 Da
- CAS
- 1415456-99-3
- PubChem CID
- 167312356
External references
Vial arithmetic
Published research contexts for Cagrilintide describe 0.3–4.5 mg per administration. Descriptive only, not a recommendation.
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 2.09× single dose
- Time to steady state
- 37.5days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Lau et al., Lancet (2021)No universal starter, maintenance cycle or blend ratio follows from these groups.
Next steps
Cagrilintide beginner guideOpen Cagrilintide planning worksheetEstimate Cagrilintide vial costTrack Cagrilintide notes